# Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

> **NCT04633902** · PHASE2 · UNKNOWN · sponsor: **California Pacific Medical Center Research Institute** · enrollment: 41 (estimated)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04633902
- **Lead sponsor:** California Pacific Medical Center Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-03
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2022-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04633902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04633902, "Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04633902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*